What is Andromeda?
Andromeda operates at the intersection of advanced robotics and healthcare innovation. Its core product, Abi, is a personalized robotic companion engineered to foster meaningful connections while simultaneously enhancing the capacity of professional care teams. By integrating sophisticated artificial intelligence with empathetic design, Andromeda addresses the growing global demand for scalable, high-quality care solutions. The company's market position is defined by its ability to alleviate the burden on healthcare providers while improving the quality of life for individuals requiring consistent support. As a key player in the Australian deeptech ecosystem, Andromeda is redefining how technology interacts with human behavior in sensitive care environments.
How much funding has Andromeda raised?
Andromeda has raised a total of $28.9M across 2 funding rounds:
Series A
$14.8M
Stock/Share Issuance
$14.1M
Series A (2025): $14.8M with participation from Forerunner Ventures, Main Sequence Ventures, Rethink Impact, and Artesian
Stock/Share Issuance (2025): $14.1M, investors not publicly disclosed
Key Investors in Andromeda
Forerunner Ventures
Forerunner Ventures partners with founders to build category-defining companies at the intersection of technology and human behavior, focusing on emerging trends and consumer demands.
Main Sequence Ventures
Main Sequence is a venture capital firm focused on deeptech, collaborating with inventors who leverage their scientific expertise to create transformative industries and address global challenges.
Rethink Impact
Rethink Impact invests in entrepreneurs and technology platforms focused on creating ecosystems of change, targeting leaders who utilize technology to address significant global challenges.
What's next for Andromeda?
With the successful closure of this major strategic investment, Andromeda is poised to transition into a phase of aggressive market expansion and product refinement. The company will likely focus on scaling its manufacturing capabilities to meet rising demand while deepening its research into adaptive AI models that further personalize the user experience. Strategic priorities will include strengthening partnerships with healthcare institutions and expanding its footprint beyond the Australian market. By maintaining its focus on mission-driven innovation, Andromeda is well-positioned to set new benchmarks in the robotics industry, ensuring that its technological advancements continue to drive measurable impact in the global care economy.
See full Andromeda company page
